KRAS and cancer: A small-molecule allosteric inhibitor of SHP-2 (RMC-4550) was found to inhibit the activity of oncogenic RAS-ERK signaling and cancer growth in models of human cancer harboring mutated BRAF, NF1 loss, or the G12C mutation of KRAS [43], suggesting that the inhibition of SHP-2 is a promising molecular therapeutic strategy for NF1-associated tumors.